Latest Conference Articles

Widespread access to CAR T-cell therapy remains a problem, and quite a few challenges have arisen in regards to optimizing outcomes for CAR T-cell therapy in patients with hematologic malignancies and solid tumors.

CD19-direct CAR T-cell therapies and the CD20-targeted bispecific antibodies both represent a viable treatment choice for patents with relapsed/refractory follicular lymphoma.

Although chemotherapy has represented the standard therapeutic modality for indolent non-Hodgkin lymphoma, monoclonal antibodies, immunomodulatory agents, targeted agents, bispecific antibodies, and cellular therapies are now available.

Allogeneic HCT has shown promise as definitive treatment for patients with relapsed or refractory AML.

In an interview, Brad S. Kahl, MD, discussed the changes in the field of follicular lymphoma and how physicians should approach treatment.

The diffuse large B-cell lymphoma treatment landscape is evolving with Pola-R-CHP and CAR T-cell therapy moving into the frontline setting.

Following positive results from the phase 1/2 EPCORE NHL-1 trial, epcoritamab is currently under evaluation across different lines of therapy and in various combinations for diffuse large B-cell lymphoma.

Data points to the loss of predictive value of an interim PET2 scan for patients with Hodgkin lymphoma when treated with a regimen containing brentuximab vedotin.

Relapsed/refractory DLBCL is associated with poor prognosis, but preclinical data suggest that adding rituximab to CD19-directed therapy such as loncastuximab tesirine may extend the duration of disease control.

Selecting and sequencing treatments in relapsed/refractory multiple myeloma involves balancing various factors due to limited historical data, as explained by Ajai Chari, MD, at the 2023 SOHO Annual Meeting.

Elizabeth "Betsy" O’Donnell, MD, discusses the importance of carrying out different strategies when treating patients with multiple myeloma who are older and frail.

Results from 2 studies shows ciltacabtagene autoleucel to prolong progression-free survival and induce response in patients with relapsed or refractory multiple myeloma.

Uwe Platzbecker, MD, discussed findings from recent phase 3 trials and their clinical implications for daily care in patients with lower-risk myelodysplastic neoplasms.

Roland Walter, MD, PhD, and Johannes Schetelig, MD, debated on the sequencing of allogeneic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia.

Venetoclax has given new hope and better options to a notoriously hard-to-treat patient group.

There are several options the frontline setting for patients with chronic phase CML, with major randomized phase 3 trials showing long-term results for second-generation tyrosine kinase inhibitors.

There was no difference in outcomes observed with intensive vs non-intensive consolidation chemotherapy regimens before allogeneic hematopoietic stem cell transplantation in elderly patients with acute myeloid leukemia.

Currently, CT/PET scans are primarily used for staging, response assessment, and surveillance, but these modalities have several limitations.

Ongoing clinical trials seek to improve minimal residual disease-negative rates and further improve event-free survival.

Eytan M. Stein, MD, discusses trials evaluating Menin inhibitors for patients with acute leukemia and unmet needs that persist in the space.

Results from the COMMANDS trial led the FDA to approve luspatercept for the treatment of anemia without prior erythropoiesis-stimulating agent use in adult patients with very low- to intermediate-risk MDS who may require regular red blood cell transfusions.

The field of mastocytosis is witnessing a paradigm shift with precision medicine in the form of mutant KIT inhibitors.

Advances are being seen with the introduction of Menin inhibitors

Triplet therapy regimens now are on the horizon for patients with AML, thanks to ongoing research into targeted therapies.

Modern fixed-duration therapy has been based on the results shown by 2 approaches: the combination of venetoclax and an anti-CD20 monoclonal antibody and the dual combination of venetoclax and ibrutinib.

With the emergence of tyrosine kinase inhibitors and targeted immunotherapies in the front line, outcomes for patients with ALL have improved. However, questions about central nervous system involvement and prophylaxis persist.

Quizartinib added to induction and consolidation chemotherapy and continued as a single agent for up to 36 cycles improves the overall survival of adults with FLT3 ITD mutated AML.

At the 11th Annual Meeting of the Society of Hematologic Oncology, a debate was held between Angela Dispenzieri, MD, and Sagar Lonial, MD, FACP, about treatment decisions for smoldering multiple myeloma.